natgillin/translations-raw huggingface dataset:
extending the hybridized capture oligonucleotides to generate a population of extension products, each of the extension products having a first portion complementary to a template polynucleotide and a second portion complementary to at least a portion of the unextended amplification oligonucleotides; 
produljivanje potporno učvršćenih veznih nukleotida koji su hibridizirani za polinukleotide kalupa, stoga stvaraju produljene produkte, produljeni produkti imaju dio komplementaran polinukleotidima kalupa i dio komplementaran s neproduljenim oligonukleotidima za umnožavanje; i
0.8% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 69% metformin hydrochloride; 3% hydroxypropyl cellulose; 20% microcrystalline cellulose; 6.5% hydroxypropyl cellulose, low substituted; and 0.8% magnesium stearate; 
(H) 0.8% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 69% metformin hidroklorida; 3% hidroksipropil celuloze; 20% mikrokristalne celuloze; 6.5% hidroksipropil celuloze, nisko supstituirane; i 0.8% magnezijevog stearata;
optionally compressing the composition obtained in step (b). 
(c) opcijski stlačivanje sastava dobivenog u koraku (b).
The selective 5HT-2C receptor agonist for use or the composition according to any one of claims 1 to 4 wherein said selective 5HT-2C receptor agonist is selected from the group consisting of: 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine; 
Pripravak u skladu sa zahtjevom 1, naznačen time, da je navedeni selektivni agonist SHT-2C receptora izabran iz skupine koju čine slijedeći spojevi i njihove farmaceutski prihvatljive soli, solvati i hidrati: 8-kloro-1-metil-2,3,4,5-tetrahididro-1H-3-benzazepin;
is selected from the group consisting of —CN, C1-4 alkyl, C3-4 cycloalkyl, cyclopropylmethyl, and cyclobutylmethyl, wherein the C1-4 alkyl of R10 is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, —OH, —CN, C1-4 alkoxy, and C1-4 haloalkoxy; and wherein each of the C3-4 cycloalkyl, cyclopropylmethyl, and cyclobutylmethyl of R10 is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, —OH, —CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxylalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; 
se bira iz skupine koju čine -CN, C1-4 alkil, C3-4 cikloalkil, ciklopropilmetil, te ciklobutilmetil, gdje C1-4 alkil u R10 može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkoksi, te C1-4 halogenalkoksi; te gdje svaki od C3-4 cikloalkila, ciklopropilmetila, te ciklobutilmetila u R10 može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkil, C1-4 halogenalkil, C1-4 hidroksilalkil, C1-4 alkoksi, te C1-4 halogenalkoksi;
An embodiment of the present invention relates to a method for encoding at least one image split into partitions, such a method implementing the steps of: 
HR P20151035 T1 PATENTNI ZAHTJEVI Postupak za kodiranje barem jedne slike podijeljene u particije, te navedeni postupak provodi slijedeće korake:
On the other hand, a thermoblock has a relatively high power consumption (e. g. 1100 Watt), such that limitations of the energy supply can lead to the requirement that only two of the three thermoblocks 3, 4 and 10 as shown in Fig. 1 can be operated simultaneously. 
S druge strane, termoblok troši relativno mnogo energije (npr. 1100 W), tako da zbog ograničenja napajanja može biti potrebno da samo dva od tri termobloka 3, 4 1 10, kao što je prikazano na Sl. 1, mogu Taditi istodobno.
The compound of claim 6, wherein the salt is a benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc salt. 
Farmaceutski prihvatljiva sol prema patentnom zahtjevu 19, naznačena time, što sol predstavlja sol benzatina, kloroprokaina, kolina, dietanolamina, etilendiamina, meglumina, prokaina, aluminija, kalcija, litija, magnezija, kalija, natrija, ili sol cinka.
An adhesive patch for the transdermal administration of a compound of formula (I): in which R1; R2, R3 and R4 are the same as or different from each other and each represents an oxo group, a hydroxy group, a mercapto group, a hydrogen atom, a halogen atom, an alkoxy group or an aryloxy group; and the dotted line indicates that there may be a single or double bond between one of the respective pairs of carbon atoms or an ester thereof, said patch comprising a substrate and a layer of adhesive on the substrate, in which said adhesive comprises a copolymer of from 40 to 60% by weight of methoxyethyl acrylate, from 30 to 40% by weight of lauryl acrylate or methacrylate and from 10 to 25% by weight of a polar monomer, said adhesive having dispersed therein at least one compound of formula (I) or an ester thereof. 
Adhezivni flaster, naznačen time što je namijenjen za transdermalnu primjenu spoja formule (I): CHF u kojoj R', R', RÅ i R" su međusobno isti ili različiti, a svaki od njih predstavlja okso skupinu, hidroksi skupinu, merkapto skupinu, atom vodika, atom halogena, alkoksi skupinu ili ariloksi skupinu; gdje iscrtkana linija označuje da tu može biti jednostruka ili dvostruka veza između jednog od odgovarajućih parova atoma ugljika ili odgovarajućeg estera, gdje navedeni flaster sadrži supstrat i sloj ljepila na supstratu, gdje navedeno ljepilo sadržo kopolimer od 40 do 60 %, težinski, metoksietil-akrilata, 30 do 40 %, težinski, lauril-akrilata ili metakrilata i 10 do 25 %, težinski, polarnog monomera, a u navedenom ljepilu je dispergiran najmanje jedan spoj formule (1) ili njegov ester.
The soluble receptor of claim 3, wherein the human FZD receptor is FZD8 and the sequence of the fragment consists of the amino acids from 28 to 158 of SEQ ID NO: 7. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da se aminokiselinska sekvenca od topivog receptora sastoji od ostataka 28 do 158 od SEQ ID NO:7, spojenih na SEQ ID NO:4.
In one embodiment, X is —C(O)—NR12—NR13—C(O)—R14, which can be depicted as formula d: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je X -C(O)-NR'"-NR *-C(O)-R'* i ima formulu d: 20.
A method for preparing a vaccine composition, comprising preparing an emulsion adjuvant according to any one of claims 1 to 8 and combining the emulsion adjuvant with an antigen. 
Postupak za pripremu pripravka za cijepljenje, naznačen time da sadrži pripremu emulzijskog adjuvanta prema bilo kojem zahtjevu od 1 do 8, te spajanje emulzijskog adjuvanta sa antigenom.
The pharmaceutical composition of any one of claims 1 to 9, wherein the composition comprises two or three additional therapeutic agents selected from HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva od 1 do 8, gdje sastav sadrži dva ili tri dodatna terapijska agensa izabrana od inhibitora HIV proteaze, ne-nukleozidnih inhibitora HIV reverzne transkriptaze, nukleozidnih inhibitoria HIV reverzne transkriptaze, nukleotidnih inhibitoria HIV reverzne transkriptaze i inhibitora HIV integraze.
Use of a di-PEGylated GLP-1 compound of any one of claims 1 to 10 in the manufacture of a medicament for the treatment of non-insulin dependent diabetes or obesity. 
Upotreba di-PEGiliranog GLP-1 spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje dijabetesa neovisnog o inzulinu ili pretilosti. t>&
The use of a combination of any one of claims 1 to 6 for the manufacture of a medicament for the treatment or prevention of conditions which can be ameliorated by the inhibition of poly(ADP-ribose) polymerase (PARP). 
Primjena spoja prema bilo kojem od zahtjeva 1 do 9, ili njegove farmaceutski prihvatljive soli, stereoizomera ili tautomera, naznačena time što služi za proizvodnju lijeka za liječenje ili prevenciju stanja koja se mogu poboljšati inhibicijom poli(ADP-riboza) polimeraze (PARP).
A method for increasing methane production in a biomass fermenting system, in which biomass is fermented under anaerobic and thermophilic conditions by a consortium comprising polymer degrading microorganisms, acetogenic microorganisms and methanogenic microorganisms, wherein methane production is increased by adding a thermophilic, anaerobic, acetogenic, hydrogen-producing bacterium selected from the group consisting of Thermotoga, Thermococcus, Pyrococcus, Clostridium, Ruminococcus and Caldicellulosiruptor genus. 
HR P20120704 T1 PATENTNI ZAHTJEVI Primjena termofilnih, anaerobnih, acetogenih bakterija koje proizvode vodik za pojačanu proizvodnju metana u sustavima za proizvodnju bioplina, naznačena time da se biomasa fermentira u anaerobnim i termofilnim uvjetima pomoću udruženih mikroorganizama koji svojim djelovanjem razgrađuju polimere, acetogenih mikroorganizama i metanogenih mikroorganizama.
characterized in that the racemic compound of the formula (XIII) is separated into its enantiomers, and the compound of the formula (XIII) 
naznačen time što se racemski spoj s formulom (XIII) razdvaja na njegove enantiomere, i spoj s formulom (XIII) NM II
With the term "formulations or pharmaceutical formulations" are intended formulations comprising 2,6-dimethoxynaphtalene or 2,7-dimethoxynaphtalene or their mixture (Endipalene) as active ingredient, in addition with other components and/or additives compatible with the pharmaceutical practice. 
Farmaceutski pripravak, naznačen time, da sadrži od 0,01 do 0,5 tež.% 2,6- dimetoksinaftalena ili 2,7-dimetoksinaftalena ili njihove smjese kao aktivnog sastojka na ukupnu težinu pripravka, uz ostale komponente i/ili dodatke, uskladive s farmaceutskom praksom.
The process according to claim 1, wherein, during step c), the temperature at which the bromination reaction is performed is from 20° C. to 40° C. below the boiling point of the volatile fatty acid. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time da je tijekom koraka c) temperatura pri kojoj se provodi reakcija bromiranja 20%€ do 40"C niža od temperature vrenja hlapljive masne kiseline.
The use of claim 35, wherein the nebulizer is configured to administer at least about 20 mg of levofloxacin or ofloxacin to the lung, preferably at least about 100 mg of levofloxacin or ofloxacin to the lung, more preferred at least about 125 mg of levofloxacin or ofloxacin to the lung, even more preferred at least about 150 mg of levofloxacin or ofloxacin to the lung. 
Uporaba iz patentnog zahtjeva 35, pri čemu se nebulizator konfigurira primijeniti najmanje oko 20 mg levofloksacina ili ofloksacina na pluća, preporučljivo najmanje oko 100 mg levofloksacina ili ofloksacina na pluća, još preporučljivije najmanje oko 125 mg levofloksacina ili ofloksacina na pluća, još preporučljivije najmanje oko 150 mg levofloksacina ili ofloksacina na pluća.
A pharmaceutical composition for use in the treatment of glaucoma, optic neuritis, or lattice dystrophy in a subject comprising a therapeutically effective amount of a monoclonal antibody or a functional fragment thereof, wherein said antibody or functional fragment thereof binds to B-amyloid protein and comprises: 
Protutijelo, ili njegov funkcionalni dio, u skladu s patentnim zahtjevom 4, naznačeno time što je namijenjeno upotrebi u liječenju u skladu s patentnim zahtjevom 4 namijenjenom smanjivanju opterećenja plakovima u sloju ganglijskih stanica u mrežnici kod subjekta koji boluje od glaukoma, optičkog neuritisa ili retikularne distrofije.
When possible, glass fiber materials having a low softening point, e.g., below about 650oC, are preferred. 
Kada je to moguće poželjni su materijali od staklenih vlakana koji imaju nisku točku omekšavanja, n.pr., ispod oko 650"C.
a Tris buffer, a histidine buffer, a glycine buffer or, preferably, a phosphate buffer (e.g. 
Tris pufer, histidinski pufer, glicinski pufer, ili pogodno fosfatni pufer (na pr.
The clip assembly according to claim 5, wherein each U-shaped clip of the sets of juxtaposed clip assemblies of which the front portions are aligned in the transverse direction include holes for securing at least one stem, wherein the holes of at least one in two juxtaposed clip assemblies of the set of juxtaposed clip assemblies are offset in a longitudinal direction in relation to holes of at least one of the contiguous clip assemblies. 
Å tipaljke prema zahtjevima 5 ili 6, naznačene time, što su u sklopovima usporednih štipaljki čiji su prednji dijelovi poredani u poprečnom pravcu, rupe za prolaz (7) sredstava za fiksiranje pomoću šipke svake druge usporedne štipaljke, pomaknute u uzdužnom pravcu u odnosu na rupe za prolaz sredstava za fiksiranje pomoću šipke susjedne štipaljke ili susjednih štipaljki.
Evaluation of Glucose, Triglyceride and Hematocrit Levels and Body Weight Gain in Diabetic Mice 
Procjena razina glukoze, triglicerida i hematokrita, te porasta tjelesne težine kod dijabetičnih miševa
The compounds of the invention are expected to find utility as analgesics in the treatment of diseases and conditions associated with pain from a wide variety of causes, including, but not limited to, inflammatory pain such as pain associated with arthritis (including rheumatoid arthritis pain and osteoarthritis pain), surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injuries (including fractures and sports injuries), and pain associated with functional bowel disorders such as irritable bowel syndrome. 
Spoj formule I prema zahtjevu 1, naznačen time, da se upotrebljava u postupku liječenja bolova iz stanja koja su odabrana od sljedećih: upalna bol, kirurška bol, organska bol, zubobolja, predmenstrualna bol, centralna bol, bol od opeklina, migrena ili cluster-glavobolja, povreda živca, neuritis, neuralgija, trovanje, ishemijska ozljeda, intersticijalni cistitis, bol kod raka, viroze, parazitske ili bakterijske infekcije, post-traumatske ozljede ili bol povezana sa sindromom osjetljivih crijeva, ili respiratorni poremećaj odabran između sljedećih: kronična opstrukcijska plućna bolest (COPD), astma i bronhospazam, pri čemu taj postupak obuhvaća davanje subjektu kojemu je to potrebno, učinkovitu količinu spoja prema zahtjevu 1.
The method of claim 1, further comprising the steps of: Performing a set partitioning on the first data-set in order to obtain a plurality of first data-subsets; 
provedbe particioniranja niza na prvom podatkovnom nizu kako bi se dobilo hijerarhijsko, višerazinsko stablo koje sadrži više prvih podatkovnih podnizova;
the third stream cooled in the heat exchanger is decompressed by decompressing means (22,52), and the third stream decompressed by the decompressing means is in a gas-liquid mixed state and both of a gas component and a liquid component of the third stream are returned to the storage tank (11). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje separator plina od tekućine (23), konfiguriran za razdvajanje BOG-a, koji se dekomprimira u plinovito-tekuće miješano stanje prilikom prolaska kroz element za dekomprimiranje (22), na plinovitu komponentu i tekuću komponentu.
The co-suspension for use of claim 30, wherein the disease or condition is selected from asthma, COPD, exacerbation of airways hyper reactivity consequent to other drug therapy, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, and pulmonary inflammation and obstruction associated with cystic fibrosis. 
Ko-suspenzija namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što se plućna bolest ili poremećaj bira između najmanje jednog od astme, COPD, pogoršanja preosjetljivosti dišnih puteva kao posljedice terapije drugim lijekom, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, respiratornog distresnog sindroma, plućne hipertenzije, te upale pluća i opstrukcije povezane s cističnom fibrozom.
Reacting the pressurized and heated feed material for a predetermined period of time; 
– reagiranju stlačenog i zagrijanog dovodnog materijala kroz zadani vremenski period;
The pharmaceutical composition of claim 12, wherein the inflammatory disease is one or more of rheumatoid arthritis; degenerative arthritis; and inflammatory diseases occurring from asthma, atopy, diabetes, or myocardial infarction. 
Spoj formule (I) iz bilo kojeg od patentnih zahtjeva 12 do 15 za njegovu primjenu prema patentnom zahtjevu 12, gdje je inflamatorna bolest jedna ili više od reumatoidnog artritisa; degenerativnog artritisa; i inflamatornih bolesti koje se javljaju kod astme, atopije, dijabetesa, ili infarkta miokarda.
glycopyrronium bromide at a dosage in the range from 5 to 26 µg per actuation; 
glikopironijev bromid u dozi u rasponu od 5 do 26 ug po aktiviranju;
baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof as active ingredients in a relative weight ratio of about 8.6/300/1, 
Sastav prema bilo kojem od prethodnih zahtjeva koji sadrži: baklofen, sorbitol i naltrekson kao aktivne sastojke u relativnom omjeru masa oko 8,6/300/1,
The method of claim 16, wherein step (b) is performed within 10 seconds to 30 minutes after step (a). 
Postupak prema zahtjevu 16, naznačen time da se korak (b) provodi tijekom 10 sekundi do 30 minuta nakon koraka (a).
In an embodiment, the size of the initial hole is extended at least in a direction away from the roots of the plant, which is the direction in which the introduced substances need to travel in most cases. 
Postupak prema zahtjevu 2, naznačen time da se veličina početnog otvora (IH) proširuje barem u smjeru udaljenom od korijena (RS) biljke (P).
In one specific formulation, the adjuvant is formulated in a single dose that contains: about 0.25 mg cholesterol; about 1.0 mg DOPC; about 50 µg 3D-MPL; and about 50 µg QS21. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se adjuvans formulira u dozi koja sadrži: otprilike 0,25 mg kolesterola, otprilike 1,0 mg DOPC, otprilike 50 ug 3D-MPL, i otprilike 50 ug QS21.
is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; 
Ri je odabran iz skupine koju čine: vodik, C;-Cgalkil, Cs-Cgcikloalkil, aril, supstituirani aril, heteroaril i supstituirani heteroaril, gdje su aril, heteroaril 1 supstituenti za aril i heteroaril prethodno definirani;
Examples of storage temperatures for formulations according to this invention are around +5°C. These temperatures are readily provided by ordinary refrigerators. 
Primjeri temperatura čuvanja za oblike prema ovom izumu su oko +5*C. Ove temperature se lako osiguravaju u običnim hladnjacima.
The dermal micro-organ according to any one of claims 1-3, wherein at least one dimension of the cross-section is 0.5-3.5 mm. 
Uporaba iz bilo kojeg od patentnih zahtjeva 1 - 3, naznačena time, da je najmanje jedan navedeni rekombinantni genski produkt prirodno proizveden u organu iz kojeg dermalni mikroorgan potječe.
a heterocyclic group, wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, each of the C1-4 alkyl groups of the above-mentioned 4), RA1, RA2, RA3 RA4, RA5 RA6, RA7, RA8 and RA9 is optionally substituted by the same or different 1 to 3 substituents selected from the following group C, and each of the C3-12 carbon ring groups of the above-mentioned 11) and RA7, and the heterocyclic groups of 12) and RA7 is optionally substituted by the same or different 1 to 5 substituents selected from the following group C, and group C is a group consisting of a halogen atom, a cyano group, 
heterociklička skupina, gdje je heterociklička skupina zasićena ili nezasićena prstenasta skupina, koja uz atom ugljika sadrži i 1 do 4 heteroatoma, koje se bira između atoma kisika, atoma dušika i atoma sumpora, svaka od C1-4 alkilnih skupina u gore navedenim 4), RA1, RA2, RA3, RA4, RA5, RA6, RA7, RA8 i RA9 su izborno supstituirane s ista ili različita 1 do 3 supstituenta, koje se bira iz sljedeće skupine C, i svaka od prstenastih skupina s C3-12 ugljika u gore navedenim 11) i RA7 i heterocikličke skupine u 12) i RA7 su izborno supstituirane s istih ili različitih 1 do 5 supstituenta, koje se bira iz sljedeće skupine C, i skupina C je skupina koju čine atom halogena, cijano skupina,
The method of claim 1, wherein the post-nerve injury rehabilitation and the administration of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt are performed on the same day. 
Derivat alkil etera predstavljen općom formulom [1] ili njegova sol za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je derivat alkil etera 1-(3-(2-(1-benzotiofen-5-il)etoksi)propil) azetidin-3-ol.
The above used expressions will be outlined in more detail below: 
Gore upotrijebljeni izrazi će se dolje objasniti s više pojedinosti:
a light chain variable amino acid sequence of SEQ ID NO: 18 and/or a heavy chain variable amino acid sequence of SEQ ID NO: 13; 
varijabilnu sekvencu aminokiselina laganog lanca SEQ ID NO: 18 i varijabilnu sekvencu aminokiselina teškog lanca SEQ ID NO: 13; ili
is independently selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, NRCRD, and (NRCRD)carbonyl; 
Rs je neovisno odabran iz skupine koja se sastoji od alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, NRcRyp 1 (NRcRp)karbonila; nje 0, 1,2, 013;
To this aim, the invention according to a first aspect relates to a floor panel of the above-mentioned specific type, with the characteristic that the pivotable lock-up body, opposite from the extremity forming the locking portion, comprises a support portion, which is rotatable against a support surface pertaining to the floor panel concerned, and more particularly is rotatable in a seat. 
Podni panel sukladno zahtjevu 1, naznačen time što potporni dio (20) u lokalnoj zoni pivota je rotatabilan u odnosu na potpornu površinu (21) koja pripada odnosnom podnom panelu, te je posebice roatatabilna u sjedištu (22).
a C3-12 carbon ring group and a heterocyclic group, wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, each of the C1-4 alkyl groups of the above-mentioned 4), RA1, RA2, RA3, RA4, RA5, RA6, RA7, RA8 and RA9 is optionally substituted by the same or different 1 to 3 substituents selected from the following group C, and 
Me naznačen time što R* je metilna skupina, Ri R* su isti ili različiti i svaki je prstenasta skupina s C,.,» ugljika ili heterociklička skupina, gdje je heterociklička skupina zasićena ili nezasićena prstenasta skupina, koja uz atom ugljika sadrži 1 1 do 4 heteroatoma, koje se bira između atoma kisika, atoma dušika i atoma sumpora, gdje su prstenasta skupina s C3.,2 ugljika 1 heterociklička skupina izborno supstituirane s 1 do 5 supstituenta, koje se bira iz sljedeće skupine B, 1
Tramadol hydrochloride and the above-stated components were mixed in a free-fall mixer. 
Tramadolhidroklorid i prethodno navedene komponente pomiješane su u gravitacionoj miješalici.
a fat/lipophilic component, in a quantity between 0% and 50% by weight of the formulation, 
- najmanje jednu masnu odnosno lipofilnu komponentu, u količini između 0 % i 50 %, težinski, formulacije,
autoimmune orchitis, wherein said antigen or ligand is a testicular antigen; 
autoimuni orhitis, pri čemu je spomenuti antigen ili ligand antigen testisa;